Poly-Zinc-Liothyronine (PZL)
Thyroid hormone replacement (inferred)
Proof-of-Concept (Human data reported)Active
Key Facts
Indication
Thyroid hormone replacement (inferred)
Phase
Proof-of-Concept (Human data reported)
Status
Active
Company
About Synthonics
Synthonics is a private, pre-revenue biotech firm founded in 2018 and headquartered in Blacksburg, Virginia, with a focus on small molecule drug development. The company's core technology involves chelating metal ions to known drug compounds to create novel Metal Coordinated Pharmaceuticals (MCPs) with superior absorption and efficacy profiles. With an initial patent granted in 2010 and a growing IP portfolio, Synthonics has demonstrated proof-of-concept in human studies and has entered into its first licensing agreement. The company operates in the niche but promising field of metallodrugs, seeking to overcome limitations of traditional organic pharmaceuticals.
View full company profile